G S Manzar, H Rafei, B Kumar, M Shanley, S Acharya, B Liu, A Xu, X A Wang, S Islam, M Kaplan, R Basar, N Uprety, R Shrestha, L Melo Garza, Y Li, P P Banerjee, M T Spiotto, B Dabaja, K Rezvani, M Daher
PURPOSE/OBJECTIVE(S): CAR-T cell therapy is limited by toxicity, high cost, logistical manufacturing issues in the autologous setting and risk of GVHD in the allogeneic setting. Substitution of T cells with NK cells opens the possibility for an allogeneic off-the-shelf product with a better safety profile. However, the inadequate efficacy of CAR-NK cells against solid tumors can be extrapolated from experience with CAR-T cells. There is limited but promising preclinical evidence that radiation therapy (RT) enhances CAR-T cell tumoricidal activity against solid tumors...
October 1, 2023: International Journal of Radiation Oncology, Biology, Physics